A drug known as Vascepa, which is a purified fish oil derivative is more effective at preventing events such as cardiovascular than ever thought before. According to a new research published in the American College of Cardiology journal, the rate of these events has been lowered by the drug in patients with higher risk counting heart attacks, strokes and deaths from cardiovascular causes by almost 30 percent versus placebo. Not only first cardiovascular events were taken into account by the study authors but also 2nd, 3rd,4th events and so on, and they thought this is better than ever before.
Amarin Pharma, Irish drug maker announced the previous results in the month of September and then after that, in the New England Journal of Medicine a new study was published in the month of November. Dr. Deepak L. Bhatt said in a statement that, by looking at the 1st events, the true underlying treatment benefit offered is been underestimated by us. Bhatt said that, with the help of this drug, we cannot just only avoid that 1st heart attack but possibly the 2nd stroke and perhaps that 3rd fatal event.
Vascepa slashed 1st events by a quarter, 2nd and 3rd events by nearly 30 percent and later events by almost a half, according to a recent data based on episodes of cardiovascular events. By treating 1000 patients for 5 years, researchers estimated that, they were able to prevent 76 coronary revascularizations, 14 strokes, 42 heart attacks, 16 hospitalizations because of unstable angina and 12 primary death associated to cardiovascular disease. Amarin funded the study. The US Food and Drug Administration approved the drug earlier in the year 2012 to lower a kind of lipid, triglycerides in excess of five-hundred mg/dL. Vascepa is derivative from a solo omega-3 fatty acid inaccessible from fish, which is a prescription drug.